Fungal Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patients

Research output: Contribution to journalReview article

Abstract

Despite advances in chemotherapy and supportive care, morbidity and mortality remain high for patients with hematologic malignancies (HMs). Those who require hematopoietic stem cell transplantation (HSCT) often require significant immunosuppression and are subject to a variety of complications. These patients carry multiple risk factors for infectious complications, including the development of invasive fungal infections, compared with the general population. Because antifungal prophylaxis has been widely adopted, there has been a shift away from invasive candidiasis toward invasive mold infections, including breakthrough infections. For patients with HM and HSCT, we outline the epidemiology, manifestations, diagnosis, and treatment of invasive fungal infections.

Original languageEnglish (US)
Pages (from-to)545-566
Number of pages22
JournalInfectious disease clinics of North America
Volume33
Issue number2
DOIs
StatePublished - Jun 1 2019

Fingerprint

Mycoses
Hematologic Neoplasms
Stem Cells
Hematopoietic Stem Cell Transplantation
Transplants
Invasive Candidiasis
Infection
Immunosuppression
Epidemiology
Fungi
Morbidity
Drug Therapy
Mortality
Population
Transplant Recipients
Invasive Fungal Infections
Therapeutics

Keywords

  • Aspergillosis
  • Candidiasis
  • Fungal infections
  • Hematologic malignancies
  • Hematopoietic stem cell transplant
  • Mucormycosis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Fungal Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patients. / Bays, Derek J.; Thompson, George Richard.

In: Infectious disease clinics of North America, Vol. 33, No. 2, 01.06.2019, p. 545-566.

Research output: Contribution to journalReview article

@article{6406adde34674573839791d8ae8e497a,
title = "Fungal Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patients",
abstract = "Despite advances in chemotherapy and supportive care, morbidity and mortality remain high for patients with hematologic malignancies (HMs). Those who require hematopoietic stem cell transplantation (HSCT) often require significant immunosuppression and are subject to a variety of complications. These patients carry multiple risk factors for infectious complications, including the development of invasive fungal infections, compared with the general population. Because antifungal prophylaxis has been widely adopted, there has been a shift away from invasive candidiasis toward invasive mold infections, including breakthrough infections. For patients with HM and HSCT, we outline the epidemiology, manifestations, diagnosis, and treatment of invasive fungal infections.",
keywords = "Aspergillosis, Candidiasis, Fungal infections, Hematologic malignancies, Hematopoietic stem cell transplant, Mucormycosis",
author = "Bays, {Derek J.} and Thompson, {George Richard}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.idc.2019.02.006",
language = "English (US)",
volume = "33",
pages = "545--566",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Fungal Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patients

AU - Bays, Derek J.

AU - Thompson, George Richard

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Despite advances in chemotherapy and supportive care, morbidity and mortality remain high for patients with hematologic malignancies (HMs). Those who require hematopoietic stem cell transplantation (HSCT) often require significant immunosuppression and are subject to a variety of complications. These patients carry multiple risk factors for infectious complications, including the development of invasive fungal infections, compared with the general population. Because antifungal prophylaxis has been widely adopted, there has been a shift away from invasive candidiasis toward invasive mold infections, including breakthrough infections. For patients with HM and HSCT, we outline the epidemiology, manifestations, diagnosis, and treatment of invasive fungal infections.

AB - Despite advances in chemotherapy and supportive care, morbidity and mortality remain high for patients with hematologic malignancies (HMs). Those who require hematopoietic stem cell transplantation (HSCT) often require significant immunosuppression and are subject to a variety of complications. These patients carry multiple risk factors for infectious complications, including the development of invasive fungal infections, compared with the general population. Because antifungal prophylaxis has been widely adopted, there has been a shift away from invasive candidiasis toward invasive mold infections, including breakthrough infections. For patients with HM and HSCT, we outline the epidemiology, manifestations, diagnosis, and treatment of invasive fungal infections.

KW - Aspergillosis

KW - Candidiasis

KW - Fungal infections

KW - Hematologic malignancies

KW - Hematopoietic stem cell transplant

KW - Mucormycosis

UR - http://www.scopus.com/inward/record.url?scp=85064279416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064279416&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2019.02.006

DO - 10.1016/j.idc.2019.02.006

M3 - Review article

C2 - 31005138

AN - SCOPUS:85064279416

VL - 33

SP - 545

EP - 566

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 2

ER -